

XPhyto Therapeutics Corp.

1 ? . Ž ((f \$ L & \$ + - , - , \$, %
 B 5 . Ž % * (* , - * ' \$ *)
 5 1 Ž * % & ' - & , \$ \$ + \$ \$
 U W j c b 4 d f c U W j Y j b j Y g r c f g " V t a

08:50 20 Apr 2020

XPhyto Therapeutics partners with German biotech firm to develop coronavirus screening test

XPhyto Therapeutics Corp (CSE:XPHY) (OTCPINK:XPHYF) said it is teaming up with a German biotech company to develop and commercialize oral screening tests for coronavirus (COVID-19).

The agreement with 3a-Diagnostics GmbH will see the two companies work on an oral, dissolvable, thin-film screening tests that will rapidly detect infectious diseases.

3a, based near Stuttgart, specializes in developing, producing and marketing point-of-care test systems.

READ: XPhyto Therapeutics brings in German infectious disease expert to advise its coronavirus test development

The agreement will also see XPhyto and 3a working together to develop 3a's existing product pipeline using XPhyto's ODF platform to administer 3a's biosensors, as well as developing a high-throughput biosensor screening platform.

XPhyto will retain an exclusive global license to commercialize all new products developed by 3a and a non-exclusive global license for the current products in development.

3a owns a proprietary biosensor platform while XPhyto specializes in manufacturing oral dissolvable thin film medical products through its 100%-owned subsidiary Vektor Pharma TF GmbH.

In a statement, XPhyto's CEO Hugh Rogers said there was a "natural synergy" between the two companies' technologies.

"By working together, we create the opportunity to quickly develop critical new products, adapt 3a's biosensor technology to Vektor's dissolvable oral delivery system and carry out EU GMP manufacturing as required," Rogers told shareholders.

Vancouver-based XPhyto will fund 3a's research and development work up to around 1.1 million euros over an 11-month period. XPhyto will also fund the adaptation of 3a's biosensor products to Vektor's ODF platform up to a total of 250,000 euros over a five-month period.

In turn, XPhyto will issue 3a 50,000 shares immediately and an additional 200,000 shares once certain COVID-19 development milestones are reached. A further 250,000 shares will be issued to 3a if the company hits 25 million euros in gross sales within 24 months.


3a will retain a 5% royalty on net sales of all products sold by XPhyto.

Vancouver-based XPhyto recently signed an exclusive advisory agreement with infectious disease expert and

Price: 2.26

Market Cap: \$137 m

1 Year Share Price Graph



Share Information

Code: XPHY

Listing: CSE

52 week High Low
 3.55 1.1

Sector: Pharma & Biotech

Website: www.xphyto.com

Company Synopsis:
 XPhyto Therapeutics Corp.

action@proactiveinvestors.com

Technical University of Munich professor Wolfgang Eisenreich to aid its efforts in developing a coronavirus test.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of XPhyto Therapeutics Corp. named herein, including the promotion by the Company of XPhyto Therapeutics Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).